Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Nuclear factor erythroid like NFE L hereafter NRF plays a
2021-09-03

Nuclear factor erythroid 2-like-2 (NFE2L2; hereafter NRF2) plays a crucial role in the basal and inducible expressions of multiple cytoprotective genes in response to electrophilic and oxidative stress [23]. The cytosolic actin-binding protein Kelch-like ECH-associated protein 1 (KEAP1) primarily re
-
br Materials and methods br Author contributions br Acknowle
2021-09-03

Materials and methods Author contributions Acknowledgments We thank members of the Skaar laboratory for critical evaluation of the manuscript. This work was supported by grants from the National Institutes of Health, R01AI069233 (EPS), and T32GM008554-21 (LJL). Introduction Pseudomonas
-
In the Hedgehog signaling pathway cholesterol is required to
2021-09-03

In the Hedgehog signaling pathway, cholesterol is required to activate SMO (Cooper et al., 2003), the downstream target of PTCH1. A previous study (Bidet et al., 2011) reported that Patched expression in yeast ll 37 increased extrusion of a fluorescent boron dipyromethanene sterol derivative (BODIP
-
Compound containing dimethylglutarimide P cap P propyl group
2021-09-03

Compound containing, dimethylglutarimide P-cap, P propyl group, α-methylbenzyl urea resulted in inhibitor with much improved binding (=0.064μM) and EC=0.3μM. This was an aza-peptide analog with an EC comparable to our first generation clinical candidate . Analog was evaluated for its selectivity aga
-
The synthesis of target compound RS C is
2021-09-03

The synthesis of target compound (RS)-C02 is illustrated as Scheme 2. Compound (RS)-3 was synthesized as reported procedures [40] and then reacted with ethyl piperidine-4-carboxylate to yield (RS)-C01, which subsequently was converted to target molecule (RS)-C02 by performing a nucleophilic substitu
-
To further explain the energy differences between
2021-09-02

. To further explain the energy differences between Group-A and Group-B, the average distances between ligands and the zinc cation were obtained from the last 1ns trajectory. It turns out that the members of group A were within the coordination distance of the zinc ion, whereas those of group B stay
-
br Conclusion br Methods br Introduction To predict such
2021-09-02

Conclusion Methods Introduction To predict such topologies, several algorithms have been developed. Quadparser (QP), developed by the Balasubramanian group have taken an approach where sequences matching G≥nN≤mG≥nN≤mG≥nN≤mG≥n model in which the lengths of G-tracts are at least n and lengths
-
Species specificity of small molecular
2021-09-02

Species specificity of small molecular GPR40 agonists have been reported by Takeda scientist. In the binding pocket of TM5, a Leu186 in human GPR40/FFA1 is replaced with Phe in rat, resulting in dramatic inter-species GPR40 activity discrepancy in certain scaffolds of small molecular GPR40 agonists.
-
It should be noted that the
2021-09-02

It should be noted that the current studies were performed in female rats. Although the oestrous cycle has been shown to modulate inflammatory processes in the periphery, data from our group has demonstrated that the phase of the oestrus cycle does not significantly alter TLR3-mediated neuroinflamma
-
Both the kK and kK
2021-09-02

Both, the kK3 and kK5-mediated ubiquitination leads to rapid internalisation of target proteins followed by lysosomal degradation, similar to that seen for MARCH-1/8 [77]. Ubiquitination activity of kK3 and kK5 depends on the positioning of the targeted lysine (or cysteine) residues [22]. The positi
-
Based on the SUMO SIM interaction involved
2021-09-02

Based on the SUMO–SIM interaction involved in SUMOD positioning, a SUMO2ΔSBD (SIM-binding domain; Q30A, F31A, I33A) mutant can be investigated that disrupts this important binding interface (Eisenhardt et al., 2015; Meulmeester, Kunze, Hsiao, Urlaub, & Melchior, 2008). In Fig. 4A, multiturnover assa
-
Long stretches of ssDNA have also been observed in
2021-09-01

Long stretches of ssDNA have also been observed in rad53-1 mutant N1-Methyl-ATP receptor under replication stress using EM images (Sogo et al., 2002). Deletion of EXO1, a 5′-to-3′ exonuclease, can suppress the generation of ssDNA detected in rad53-1 mutant cells (Cotta-Ramusino et al., 2005). It wa
-
Interestingly genome wide association studies have linked
2021-09-01

Interestingly, genome-wide association studies have linked the chromosomal region harboring RDHE2 (SDR16C5) and seven other genes to stature and growth in cattle, humans, and pigs [30], [31], [32], [33], [34], [35], [36], [37], and beak deformity in chickens [38]. The most recent study specifically
-
In conclusion DDR ECD was shown to be
2021-09-01

In conclusion, DDR1 ECD was shown to be sufficient for collagen mediated DDR1 oligomerization, and the oligomerized form binds to collagen with increased affinity. In full length receptors expressed on live cells, DDR1 oligomerization occurred on the cell surface in agreement with the role of DDR1 E
-
The field of synthetic cytokine biology
2021-09-01

The field of synthetic cytokine biology continues to grow through molecular, physiological and pathophysiological insights, as well as via new methodical advances. The approval of chimeric antigen receptor (CAR) T cell immunotherapy by the US Food and Drug administration (FDA) in August 2017 for rel
15953 records 607/1064 page Previous Next First page 上5页 606607608609610 下5页 Last page